Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2

Group 1 - The group caters to both novice and experienced biotech investors, providing insights on catalysts, buy and sell ratings, and product sales forecasts for major pharmaceutical companies [1] - It offers integrated financial statements, discounted cash flow analysis, and market-by-market analysis to aid investment decisions [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the investing group Haggerston BioHealth and has compiled detailed reports on more than 1,000 companies [1]